You are here

Article Text

Article menu

Download PDFPDF

PostScript
Correspondence
Letter to the editors
Free
  1. Jørgen Vestbo1,2,
  2. Roberto Rodriguez-Roisin3
  1. 1Respiratory Research Group, University of Manchester, Manchester, UK
  2. 2Department of Respiratory Medicine, Odense University Hospital and University of Southern Denmark, Odense, Denmark
  3. 3Department of Pneumologia, Hospital Clinic, Barcelona, Spain
  1. Correspondence to Professor Jørgen Vestbo, Respiratory Research Group, University of Manchester, Manchester M23 9LT, UK; jorgen.vestbo{at}manchester.ac.uk

https://doi.org/10.1136/thoraxjnl-2012-203044

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest your ‘Highlights from this Issue’ in the November issue of Thorax.1 We noticed that you had a fresh comment on Global Initiative for Obstructive Lung Diseases (GOLD) not recommending macrolides to prevent exacerbations of chronic obstructive pulmonary disease (COPD).

    We also noted that you hinted that it was probably too cheap for GOLD—suggesting that we were in the pockets of ‘big pharma’. We find the remark hurtful and wrong. GOLD does …

    View Full Text

    Linked Articles